Cancer is tough on individuals and families. While there is physical and mental side to battle out another dimensions which adds to the burden is the cost of diagnosis and treatment.
But what if there was a way to detect cancer early, when it is most treatable, and reduce the financial and emotional burden of cancer care? That’s the goal of a groundbreaking partnership between John Hancock, Munich Re, and Grail.
Role of life insurer
John Hancock, a US-based life insurance company, has long been committed to using technology and innovation to improve the health and well-being of its policyholders. As part of this commitment, the company has developed the Vitality program, which incentivizes healthy behaviors and offers rewards to policyholders who take steps to improve their health.
One of the rewards offered by the Vitality program is a free cancer screening. But what makes the John Hancock cancer screening unique is its personalized approach to cancer screening based on an individual’s risk profile. Policyholders are screened for cancer based on their age, gender, family history, and other risk factors, which means that individuals who are at higher risk of developing certain types of cancer may receive more frequent or targeted screenings.
Role of Cancer Diagnosis company
This is where Grail comes in. Grail is a US-based healthcare company that is developing a blood test that can detect cancer at an early stage, even before symptoms appear. By analyzing fragments of DNA that are released into the bloodstream by cancer cells, the Grail test can identify the presence of cancer in the body. Through its partnership with Grail, John Hancock plans to offer its policyholders access to this innovative cancer detection technology. Policyholders who participate in the Vitality program and meet certain criteria may be eligible for a free Grail test.
Role of insurance major
And Munich Re, a global reinsurance company, is playing a critical role in this partnership by providing financial and underwriting support through its subsidiary, Munich Re US Life. This support includes risk assessment, product development, and underwriting expertise. Munich Re’s involvement highlights the growing importance of collaboration between insurance companies, healthcare companies, and technology providers in developing innovative solutions to improve health outcomes and reduce the cost of healthcare.
The John Hancock-Munich Re-Grail partnership is leading the world in cancer screening innovation. By leveraging cutting-edge technology, personalized risk assessment, and underwriting expertise, this partnership is helping to detect cancer early and reduce the financial and emotional burden of cancer care. It’s a powerful example of what can be achieved when companies collaborate to tackle some of the most pressing health challenges of our time.
Boundaryless Thinking triggers
Bringing together key players to deliver a compelling value proposition.
| I would like to apply boundaryless thinking | |
| with ideas on | teaming strategy, design product, increase awareness |
| which can be applied in | tackling complex problems, building a strong ecosystem |
| in areas like | Government, Education, Technology, Utilities |
Reference
https://www.munichre.com/en.html
https://grail.com/press-releases/
